Comparative Pharmacology
Head-to-head clinical analysis: BRISTAGEN versus HUMATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRISTAGEN versus HUMATIN.
BRISTAGEN vs HUMATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bristagen (amikacin) is an aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis.
Aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional proteins.
1-2 mg/kg IM or IV every 8-12 hours; typical adult dose is 1 mg/kg every 8 hours.
15-25 mg/kg/day orally in 4 divided doses for hepatic coma; 50 mg/kg/day orally in 4 divided doses for infectious diarrhea, max 4 g/day.
None Documented
None Documented
2.5 hours (prolonged to 20-40 hours in renal impairment).
2-3 hours (serum half-life of absorbed fraction); clinically negligible due to minimal systemic absorption
Renal (90% unchanged via glomerular filtration); biliary/fecal excretion <10%.
Primarily unchanged in feces (~90%); small amount absorbed is excreted renally as unchanged drug (~1%)
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic